Podcasts about savr

Listener feedback, more long-term data on the TAVR/SAVR question, population prevalence of valvular heart disease in the US, and a CMS proposal to expand TAVR coverage are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback ICD Trends and Outcomes: 15-Year Analysis https://doi.org/10.1093/europace/euag110 MADIT-RIT https://www.nejm.org/doi/full/10.1056/NEJMoa1211107 II More Long Term Data on TAVR vs SAVR PARTNER 2 Trial https://www.jacc.org/doi/10.1016/j.jacc.2026.03.169 10-Year Outcomes of SAPIEN 3 TAVR or SAVR in Intermediate-Risk Patients https://doi.org/10.1016/j.jacc.2026.03.170 TAVR at a Decade: Editorial https://doi.org/10.1016/j.jacc.2026.04.042 EVOLUT Trial https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063 Updated 5-year Outcomes of TAVR vs SAVR in AS https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092 NOTION Trial https://doi.org/10.1093/eurheartj/ehae043 PARTNER 3 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2509766 NOTION 2 Trial https://academic.oup.com/eurheartj/article/45/37/3804/7673297 TAVR vs SAVR Editorial : https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehag407/8708044 III The PREVUE-VALVE Study PREVUE-VALVE Study https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5137 IV CMS has Proposed New Coverage for TAVR CMS Proposal Document https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&ncaId=321 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Savršenim vikendom u Mađarskoj, Marc Marquez došao to svoje istorijske 100. pobede. Do 100. pobede za Dukatijev fabrički tim. Kao i do maksimalmnih 37 poena u momentu kada je Jorge Martin rešio da igra na sve ili ništa i obori čak pet rivala MM93 u odbrani titule...OMV, ZVANIČNI PARTNER LAP 76 ⛽️Preuzmite OMV MyStation mobilnu aplikaciju, podržite Lap 76 - https://www.omv.co.rs/sr-rs/mystationPretvorite poene u trenutke radosti - svaka kupovina na OMV stanicama vam donosi poene, koje možete pretvoriti u trenutke radosti u prodavnici OMV-a.Pri kupovini goriva, preporučujemo MaxxMotion, za koji ostvarujete i popust!

We are introducing you to the 326th Album of the Week - 'Siempre Marginal' by Savršeni Marginalci, exclusively talking to Tin, TereT and Savršeni Marginalci, offering the HR Top 100 chart changes and bringing the local music news. Host: Ana Radišić

We are introducing you to the 324th Album of the Week - 'Eksterminator '81' by Toni Starešinić, exclusively talking to Gina, Selestia, Miris Grada, Toni Starešinić and Branko Komljenović, offering the HR Top 100 chart changes and bringing the local music news. Host: Ana Radišić

U 77. epizodi Njuz POPkasta, gošća je književnica Lana Bastašić. Dok Nenad i Jelisaveta pokušavaju da izgovore njeno ime kako dolikuje, Lana nam objašnjava kako je to biti pisac čiju je knjigu Carrie Bradshaw (da, ona iz „Seks i grada“) okačila na svoj Instagram story, a da niko u lancu – od agenta do izdavača – nema pojma kako se to zapravo desilo. Razgovaramo o tome zašto su „teške“ teme postale omiljena literatura novih generacija, kako izgleda proces rada sa urednicima (kad se ne svađaju oko izbačenih pasusa) i zašto nam je toliko teško da danas pročitamo deset stranica knjige bez provere notifikacija. Analiziramo i dokumentarni film Luisa Terua, u kojem on sa svojom prepoznatljivom radoznalošću istražuje digitalne zajednice koje kreiraju influenseri. Lana nam otkriva i ekskluzivu o novom romanu koji piše na našem jeziku, nakon što je prethodni „proterala“ kroz anglosaksonsku marketinšku mašineriju. Uz neizbežnu muzičko-filmsku „svaštaru“, saznajte zašto su serije o „nesavršenim ljudima“ postale teme za ozbiljne razgovore, dok naša redakcija brani albansku književnost i makedonski rejv kao vrhunske domete kulture. Spremite Njuz šolje i pretplatite se na kanal! PRIJATELJI EPIZODE: - Generali osiguranje: Putujete po Srbiji ili van nje? Naši prijatelji iz Generali osiguranja vas podsećaju da vizuelizacija pada na ulici nije najzabavniji hobi.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Dr. John Forrest, a cardiologist and Director of both Interventional Cardiology and the Structural Heart Disease Program at Yale Medicine, New Haven, CT, USA, about a paper he authored titled “Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis,” published by the Journal of the American College of Cardiology. Chapters 00:00 Intro  02:38 TAVR vs SAVR Context  03:54 CDC WONDER Data, TAVR SAVR  05:37 JANS 1, TAVR vs SAVR 5-Year Outcomes  07:31 JANS 2, Temporary MCS Devices Landscape  09:17 JANS 3, Pulm Resection Post-CABG  10:23 JANS 4, PRE-HIIT Randomized Trial  12:36 Career Center  13:10 Video 1, Redo MVR After VIV TAVR  15:37 Video 2, Repair After Acute Intramural Hematoma  18:01 Video 3, Acute Severe MR Repair  19:36 Dr. Forrest, 6-Year TAVR vs SAVR  44:49 Upcoming Events  45:33 The Lifeline Podcast  They explored other randomized trials involving high-risk and intermediate-risk patients with aortic stenosis and examined the specific goals of this low-risk trial. The discussion then delved into the trial's results, highlighting that there was no significant difference in the composite endpoint of all-cause mortality or disabling stroke. However, a noteworthy finding was that the transcatheter aortic valve replacement (TAVR) arm experienced a higher reintervention rate compared to surgery, primarily due to an increased incidence of aortic regurgitation. They also addressed factors such as valve dilation, stents, and various reasons for surgical valve failure. Additionally, they examined the similarities between this trial and other partner trials and the future for low-risk patients with aortic stenosis.   Joel also highlights recent JANS articles on the updated five-year outcomes of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low- to intermediate-surgical risk, a United States nationwide analysis on the changing landscape of temporary mechanical circulatory support devices in the new heart allocation system, pulmonary resection post-coronary artery bypass grafting, and a randomized controlled trial on the preoperative exercise to improve fitness in patients undergoing complex surgery for cancer of the lung or esophagus (PRE-HIIT).  In addition, Joel explores redo mitral valve replacement after previous valve-in-valve mitral TAVR, aortic repair after acute intramural hematoma, and repair of acute severe mitral regurgitation due to iatrogenic papillary muscle rupture. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) Updated 5-Year Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Low- to Intermediate-Surgical Risk  2.) The Changing Landscape of Temporary Mechanical Circulatory Support Devices in the New Heart Allocation System—A United States Nationwide Analysis  3.) Pulmonary Resection Post-Coronary Artery Bypass Grafting: Feasible, but Right-Sided Procedures Demand Caution  4.) Preoperative Exercise to Improve Fitness in Patients Undergoing Complex Surgery for Cancer of the Lung or Esophagus (PRE-HIIT): A Randomized Controlled Trial  CTSNet Content Mentioned  1.) Redo Mitral Valve Replacement After Previous Valve-in-Valve Mitral TAVR  2.) Aortic Repair After Acute Intramural Hematoma   3.) Repair of Acute Severe Mitral Regurgitation Due to Iatrogenic Papillary Muscle Rupture  Other Items Mentioned  1.) Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis  2.) The Lifeline: End-Tidal Carbon Dioxide Monitoring in Cardiac Surgical Emergencies  3.) Instructional Video Competition     4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning spoke with Drs. Mateo Marin-Cuartas, CTSNet JANS Editor and cardiac surgeon at the University Department of Cardiac Surgery at Leipzig Heart Centre University Hospital in Leipzig, SN, Germany; and Samuel Heuts, a cardiothoracic surgeon in the Department of Cardiothoracic Surgery at Maastricht University Medical Center in Maastricht, LI, about a paper they authored titled “Updated 5-Year Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Low- to Intermediate-Surgical Risk,” published in Heart, a journal produced by the British Medical Journal. Chapters 00:00 Intro 01:51 JANS 1, 6-Year Outcomes TAVR vs SAVR 06:45 JANS 2, Evolut THV Postdilation 09:22 Video 2, TAVI in SAVR Explantation 11:10 JANS 3, High Risk Increasing Adoption of DCD 13:17 JANS 4, Lobar Quantitation for Assessment 15:16 Video 1, Narayana Robotic AVR 17:23 Video 3, Extended Resections Podcast 18:30 Dr. Marin-Cuartas & Heuts, TAVR vs SAVR 36:42 Upcoming Events 37:32 Instructional Video Competition 38:55 Career Center They discussed the motivations behind the creation of this paper and provided insights into its Bayesian hierarchical design. Key findings included the five-year all-cause mortality rates and the risk of stroke associated with the procedures. They also referenced other studies with similar findings, such as a recently published paper from the Journal of the American College of Cardiology on the “Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis.” Finally, they explored the future of transcatheter aortic valve implantation and surgical aortic valve replacement.   Joel also highlights recent JANS articles on the six-year outcomes after transcatheter vs surgical aortic valve replacement in low-risk patients with aortic stenosis, postdilation of Evolut transcatheter heart valves, insights into current practices in the United States regarding increasing adoption of donation after circulatory death in high-risk heart transplant recipients, and the value of V/Q SPECT/CT lobar quantitation for pre-treatment assessment of lung malignancy.  In addition, Joel explores robotic-assisted aortic valve replacement, TAVI in SAVR explantation, and an episode of The Atrium podcast featuring host Dr. Alice Copperwheat speaking with Dr. Maninder Kalkat about extended resections. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) Six-Year Outcomes After Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis  2.) Postdilation of Evolut Transcatheter Heart Valves: Insights From Bench Testing  3.) Increasing Adoption of Donation After Circulatory Death in High Risk Heart Transplant Recipients: Insights Into Current Practices in the United States  4.) The Value of V/Q SPECT/CT Lobar Quantitation for Pre-Treatment Assessment of Lung Malignancy  CTSNet Content Mentioned  1.) Robotic-Assisted Aortic Valve Replacement   2.) TAVI in SAVR Explantation: A Two-Step Technique for Successful Removal   3.) The Atrium: Extended Resections   Other Items Mentioned  1.) Updated 5-Year Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Low- to Intermediate-Surgical Risk  2.) The Lifeline  3.) Instructional Video Competition     4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Kad se približiš četrdesetima, tijelo počinje biti… drugačije. Hormoni se pomiču, ovulacija postaje glasnija, stres i umor se brže vide. Ne samo da izgledamo drugačije, osjećamo se drugačije. A koža? Koža pamti sve.Ponekad smo prve znakove promjena primijetile tek na licu, dok se mentalno i dalje borimo osjećati ‘normalno'. Ukratko – borba.Tridesete, a onda i četrdesete ipak donose nešto novo. Faza je to  u kojoj počinjemo bolje razumjeti sebe. Istina, nekad nas umara i konstantan rad i vječna očekivanja. Tako da je ponekad taj rad zapravo briga o sebi. Ovdje ulazi važna lekcija: jednostavna i funkcionalna njega kože može biti poput svjetla na kraju tunela.  Nivea LUMINOUS630 linija nije tu da briše godine, nego da ujednači ten, vrati sjaj i podrži kožu koja pamti život. Bez pritiska da budeš savršena. Jer nijedna od nas to nije.Savršenstvo je precijenjeno. 

EVOLUT Low Risk data, a provocative meta-analysis, DNR orders, targeted hypothermia, good news in HFpEF evidence, and GLP-1s as AF drugs are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I EVOLUT Low Risk 6-year Results and a 5-year Meta-Analysis of TAVR vs SAVR 6-Year Outcomes of TAVR vs SAVR https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063 EVOLUT Low Risk Trial at 2 years https://www.nejm.org/doi/full/10.1056/NEJMoa1816885 EVOLUT Low Risk Trial at 3 years https://www.jacc.org/doi/10.1016/j.jacc.2023.02.017 EVOLUT Low Risk Trial at 4 years https://www.jacc.org/doi/10.1016/j.jacc.2023.09.813 Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials https://www.jacc.org/doi/10.1016/j.jacc.2019.08.1034 TAVR vs SAVR 5-Year Outcomes - Systematic Review https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092 TAVR vs SAVR Updated Meta-Analysis of RCTs https://www.jacc.org/doi/10.1016/j.jacc.2024.12.031 UK TAVI Trial https://jamanetwork.com/journals/jama/fullarticle/2792251 Dr David Cohen on X https://x.com/djc795/status/2023556582030852172?s=46&t=zXMCUoVjSsdyemzWlzeBjA II DNR in the Hospital Inadequate Documentation of Unilateral DNR Orders https://jamanetwork.com/journals/jama/fullarticle/2829203 GeriPal Blog Unilateral DNR Orders https://geripal.org/unilateral-dnr-gina-piscitello-erin-demartino-will-parker/ III Yet another failure of Targeted Hypothermia 2-Year Follow-Up of TTM2 Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2845193 TTM2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2100591 IV Good news in HFpEF Evidence ALT-FLOW II Trial https://doi.org/10.1093/ejhf/xuaf016 V GLP-1 as AF drugs Semaglutide as Adjunctive Therapy in Obesity-Related PAF https://doi.org/10.1093/europace/euag018 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Det är nytt år och det betyder att vi ska kolla nya case och sätta väskan för 2026. Vi har med oss fina Quanor som huvudsponsor! Kika in quanor.se idag!Sedvanligt snack om ditten och datten, men sedan går vi in på det som vi ska. Vi har 25+ case som ska tittas till. Så här ser det ut:I-Tech AlligoVertiseitAdvenicaGomeroCareiumC-tekITABEQL PharmaAvtechPaxmanHoveNordisk BergteknikmResellFreetrailerSedan några snabba i form av:Green LandscapingSvedbergsInfracomHacksawC-radPlejdShellyLumenradioDelliaFullt ös medvetslös, men portföljen får fyra nya innehav och fyra åker ut. Det kan bli snabba byten i hockey dock men vi känner oss ganska nöjda till slut. Vi tipsar också om den nya tjänsten Quanor. En mycket spännande tjänst för börsnördar, som vi hoppas kommer att utvecklas till ett fantastiskt verktyg. Kika in quanor.se idag!Kolla in vår portfölj på Twitter/X och Bluesky: @GottTjotAktierMaila in till: gotttjotomaktier@gmail.comFölj oss på Twitter/X och Bluesky: @GottTjotAktier, @MarkusGedda & @aktiehesten-(00:06:47) - SAVR-portföljen(00:12:48) - I-Tech(00:21:52) - Alligo(00:32:38) - Vertiseit(00:43:11) - Advenica(00:51:10) - Gomero(00:58:32) - Careium(01:05:28) - C-tek(01:14:47) - ITAB(01:21:12) - EQL Pharma(01:26:42) - Avtech(01:33:44) - Paxman(01:36:57) - Hove(01:41:30) - Nordisk Bergteknik(01:48:44) - mResell(01:52:46) - Freetrailer(01:56:33) - Green Landscaping(01:57:14) - Svedbergs(01:57:44) - Infracom(01:59:16) - C-rad(02:00:25) - Hacksaw(02:01:05) - Plejd(02:03:07) - Shelly(02:04:22) - Lumenradio(02:07:09) - Dellia(02:08:15) - Portföljen 2026Support this show http://supporter.acast.com/nantingomaktier. Hosted on Acast. See acast.com/privacy for more information.

Det är dagen före dopparedagen och årets sista avsnitt. Vi har med oss SAVR och fina Quanor som varit med oss under året.Sedvanligt snack om ditten och datten, allt från att staten inte ska utveckla mjukvara till läckt information på tvivelaktiga sajter.När det är jul så tänker alla så klart på iGaming (00:33:54) och det blir en sista update om Brasilien och Finland som vaskat fram lite beslut så här i slutet av året.Vi rundar av vår SAVR-portfölj (00:39:57) för året som utvecklats väldigt fint. 50%+ i avkastning och det får man så klart vara nöjd med. Vi snackar kort om året och vår egen utveckling och ser framemot en vända med nya bolag inför 2026.Vuxen Group (00:55:48) har också rapporterat med sitt brutna räkenskapsår. Det händer grejer och rapporten var minst sagt i rätt riktning. Kul tycker vi som anser att renodlingen mot sexuell hälsa är helt rätt väg framåt. Billigaste e-handelsbolaget på börsen vaknar till liv?Vi avslutar sedan med en Veckans Volley i sedvanlig ordning. Och önskar våra sponsorer och lyssnare en god jul!Vi tipsar också om den nya tjänsten Quanor. En mycket spännande tjänst för börsnördar, som vi hoppas kommer att utvecklas till ett fantastiskt verktyg. Kika in quanor.se idag!Vi har också med oss SAVR som sponsor som du hittar hos https://savr.com. Handla aktier, fonder och ETF:er med automatiskt courtage!Kolla in vår SAVR-portfölj på Twitter/X och Bluesky: @GottTjotAktierMaila in till: gotttjotomaktier@gmail.comFölj oss på Twitter/X och Bluesky: @GottTjotAktier, @MarkusGedda & @aktiehesten-(00:09:42) - Nyheter(00:10:02) - Infracom(00:18:08) - Statlig digitalisering(00:26:17) - Pornhub-läckan(00:27:48) - Chrippa-domen(00:33:54) - iGaming-nyheter(00:39:57) - SAVR-portföljen 2025(00:55:48) - Vuxen Group(01:16:19) - Veckans VolleySupport this show http://supporter.acast.com/nantingomaktier. Hosted on Acast. See acast.com/privacy for more information.

Det börjar närma sig dopparedagen, men det betyder inte att vi ligger på latsidan. Nej då, ett nytt avsnitt blir det. Med oss ha vi så klart SAVR och fina Quanor!Det blir lite löst snack som vanligt och lite nyheter. Vi pratar bland annat om Dellias förvärv av Kirirom som verkade uppröra de som inte äger aktien. Många har frågat efter iGaming (00:30:56) och självklart lyssnar vi. Hästen vevar igång med lite allt möjligt från Italiens nya regleringsmanöver till Evokes strategiska översyn. Addabbo är tillbaka och se så klart ljust på framtiden. Avslutningsvis blir det lite vår syn på iGaming-bolagen framåt (00:57:09). Hacksaw och Betsson lockar. Evolution borde locka men vi är för fega. Kambi kan leverera på kort sikt, men det långa caset känns lite skakigt. Gedda har sedan tittat till våra onlineapotek Apotea och MEDS (01:16:26). Apotek online känner vi vara en given nisch som bör kunna växa strukturellt i många år. Apotea är den stora pjäsen och MEDS är utmanaren. Gedda jämför och jämför, och vi landar väl halvt i att utmanaren MEDS känns mest spännande trots allt. Vi avslutar sedan med en Veckans Volley i sedvanlig ordning. Vi tipsar också om den nya tjänsten Quanor. En mycket spännande tjänst för börsnördar, som vi hoppas kommer att utvecklas till ett fantastiskt verktyg. Kika in quanor.se idag!Vi har också med oss SAVR som sponsor som du hittar hos https://savr.com. Handla aktier, fonder och ETF:er med automatiskt courtage!Kolla in vår SAVR-portfölj på Twitter/X och Bluesky: @GottTjotAktierMaila in till: gotttjotomaktier@gmail.comFölj oss på Twitter/X och Bluesky: @GottTjotAktier, @MarkusGedda & @aktiehesten-(00:07:40) - Addvise(00:13:01) - Envar(00:19:44) - Dellia(00:30:56) - iGaming-nyheter (00:31:02) - Hacksaw (00:33:08) - Brasilien (00:38:27) - Betsson (00:48:43) - Gaming corps (00:54:23) - New York (00:55:46) - Nya Zeeland(00:57:09) - iGaming 2026 (00:58:35) - Hacksaw (01:02:46) - Betsson (01:05:36) - Evolution (01:08:36) - Kambi(01:16:26) - Meds & Apotea(01:57:21) - Veckans volleySupport this show http://supporter.acast.com/nantingomaktier. Hosted on Acast. See acast.com/privacy for more information.

We are introducing you to the 308th Album of the Week - 'Amarchord' by Kristijan Beluhan, offering the HR Top 100 chart changes and bringing the local music news. Host: Ana Radišić

En vecka närmre julafton, snart Lucia och Gött Tjöt börjar komma ikapp sin fina backlogg. I denna vecka blir det nyheter och tre intressanta bolag: två gamla bekantskaper och en ny. Det blir idag fokus på Formpipe (00:28:29) eller Lasernet som de snart heter, Online Brands Nordic (00:51:05) och även Adtraction (01:26:21). Vi börjar med lite löst snack som vanligt och det blir lite casino och Netflix bland annat. Gedda tittar sedan till mjukvaruboalget Formpipe (00:28:29). Pipen ska snart byta namn till Lasernet, ett namn som för tankarna till 90-talet och filmer på VHS. Delar ska avyttras, renodling ska göras och lönsamhet ska upp? Eller?Vi smyger oss vidare till Online Brands Nordic (00:51:05) eller OBAB som de lite coolare säger. Hästen har djupdykt i OBAB, och försöker att inte bli för långrandig i dagens avsnitt. Caset har en tung styrelse, ledning och ägarlista som gör att man ryggar till. Spännande grejer. Sist blir det Adtraction (01:26:21) - Kungarna inom affiliation och partner marketing. Gedda kryssar fram bland svåra begrepp och tycker det ser väldigt billigt ut. Vi avslutar sedan med en Veckans Volley i sedvanlig ordning. Vi tipsar också om den nya tjänsten Quanor. En mycket spännande tjänst för börsnördar, som vi hoppas kommer att utvecklas till ett fantastiskt verktyg. Kika in quanor.se idag!Vi har också med oss SAVR som sponsor som du hittar hos https://savr.com. Handla aktier, fonder och ETF:er med automatiskt courtage!Kolla in vår SAVR-portfölj på Twitter/X och Bluesky: @GottTjotAktierMaila in till: gotttjotomaktier@gmail.comFölj oss på Twitter/X och Bluesky: @GottTjotAktier, @MarkusGedda & @aktiehesten-(00:07:29) - Nyheter(00:28:29) - Formpipe(00:51:05) - Online Brands(01:26:21) - Adtraction(01:50:48) - Veckans VolleySupport this show http://supporter.acast.com/nantingomaktier. Hosted on Acast. See acast.com/privacy for more information.

Vi är inne i julens månad, men det är fullt fokus som vanligt ändå. Vi börjar med löst tjöt som alltid och går sedan in på det vi ska. Vi tittar till SAVR-portföljen (00:18:37) så här efter Q3-rapporterna. Det här gått starkt i år med 52,5% hittills och nu går vi in i slutspurten. Vi går igenom våra tankar kring innehaven och vi är rätt nöjda. Det blir således snack om Cheffelo, Premium Snacks, Lammhult, Nelly, Storytel, Unlimited Travel Group, Generic och Hellofresh. Vi släpar oss sedan vidare till Danmarks stolthet Freetrailer (00:58:39). Gedda snackar utilization rate, geografiska marknader och projekt Mont Blanc. Nikolai rattar Freetrailer väl, men är det en aptitlig värdering? Sedan blir det kvalitetscaset Svedbergs Group (01:23:36). Bolaget har parerat de tuffa tiderna inom bygg på ett fabulöst sätt genom bland annat några högpresterande förvärv. balansräkningen gör bolaget redo för nya förvärv, och det var senast 2023 som vi fick se Svedbergs på shoppinghumör. Värderingen är inte direkt en ”serieförvärvarvärdering ala Röko”, utan marknaden gör en tydlig skillnad badrumsförvärvare och badrumsförvärvare. Låg värdering, varumärket Svedbergs stärker lönsamheten, bättre bygg- och renoveringsmarknad och ett nytt förvärv är ändå ett intressant recept. Vi avslutar sedan med en Veckans Volley i sedvanlig ordning. Vi tipsar också om den nya tjänsten Quanor. En mycket spännande tjänst för börsnördar, som vi hoppas kommer att utvecklas till ett fantastiskt verktyg. Kika in quanor.se idag!Vi har också med oss SAVR som sponsor som du hittar hos https://savr.com. Handla aktier, fonder och ETF:er med automatiskt courtage!Kolla in vår SAVR-portfölj på Twitter/X och Bluesky: @GottTjotAktierMaila in till: gotttjotomaktier@gmail.comFölj oss på Twitter/X och Bluesky: @GottTjotAktier, @MarkusGedda & @aktiehesten-(00:10:58) - Nyheter(00:18:37) - SAVR-portföljen (00:28:02) - Hellofresh (00:32:22) - Generic (00:37:03) - Unlimited Travel Group (00:40:11) - Storytel (00:44:17) - Nelly (00:47:07) - Lammhult (00:49:36) - Premium Snacks (00:55:13) - Cheffelo(00:58:39) - Freetrailer(01:23:36) - Svedberg Group(01:46:41) - Veckans VolleySupport this show http://supporter.acast.com/nantingomaktier. Hosted on Acast. See acast.com/privacy for more information.

Efter event och händelserika dagar är vi tillbaka. Vi har varit på Börspadel i Stockholm och annat. Trevligt. Idag har vi med oss Edvin Malmgård (01:20:37) en gammal go Skövdebo och Twitterprofil. Mannen som satt snegunga på kartan är även IR-ansvarig i Räkan och lite annat. Han snackar även om nya tjänsten Quanor som han också varit med och grundat. Bra surr utlovas. Edvin ger även ett Black Week-erbjudande där man får testa Quanor för 39kr/mån i 3 månader!Vi har med oss alla våra fina sponsorer som vanligt idag:Sveriges bästa handelsplattform: SAVRPinPoint - Din bästa vän i rapporttiderQuanor - Finansiell AI som alltid är till hjälp. Men innan det blir det löst snack om allt från Intellego till Kinnevik. Inte de vanligaste ämnena kanske… Sedan blir det Dellia Group (00:23:58) som kom med en riktigt banger till rapport. Norsk mango är på allas läppar på flera sätt. Aktien gått starkt sedan IPO, men känns fortsatt aptitlig. Sedan över till Paxman (00:42:41) där Gedda guidar oss genom forskning, reimbursement och CIPN. Ett lönsamt forskningsbolg säger Gedda. Och kanske kan det vara intressant?Sist ut bland bolagen blir Opter (01:09:09). Informationen är knapphändig och IR-arbete prioriteras inte. Man tuffar dock på relativt stabilt trots tuff marknad. Vi avslutar sedan med en Veckans Volley i sedvanlig ordning. Vi tipsar också om den nya tjänsten Quanor. En mycket spännande tjänst för börsnördar, som vi hoppas kommer att utvecklas till ett fantastiskt verktyg. Kika in quanor.se idag!Vi har med oss fina PinPoint idag som vanligt i rapportperioden. Din vän i rapportperioden så bara att gå in på https://pinpointestimates.com. Vi har också med oss SAVR som sponsor som du hittar hos https://savr.com. Handla aktier, fonder och ETF:er med automatiskt courtage!Kolla in vår SAVR-portfölj på Twitter/X och Bluesky: @GottTjotAktierMaila in till: gotttjotomaktier@gmail.comFölj oss på Twitter/X och Bluesky: @GottTjotAktier, @MarkusGedda & @aktiehesten-(00:11:06) - Nyheter(00:11:11) - Intellego(00:16:40) - Kinnevik(00:23:58) - Dellia Group(00:42:41) - Paxman(01:09:09) - Opter (01:20:37) - Intervju med Edvin Malmgård(02:01:04) - Veckans VolleySupport this show http://supporter.acast.com/nantingomaktier. Hosted on Acast. See acast.com/privacy for more information.

På't igen! Nya tag och äntligen dags för Hacksaw som många har önskat, men även mycket annat. Bland annat en intervju med Actics vd Niklas Johansson som berättar om bolaget. Vi har med oss alla våra fina sponsorer som vanligt idag:Sveriges bästa handelsplattform: SAVRPinPoint - Din bästa vän i rapporttiderQuanor - Finansiell AI som alltid är till hjälp. Vi kör första lite ”kortare” dragningar om Angler Gaming (00:11:53), Envar (00:23:53), Infracom (00:30:54) och så klart Generic (00:36:08). Vi dundrar in i avsnittets höjdpunkter och först ut blir Hacksaw (01:02:44). Bolaget kommer in med en fin Q3-rapport. Stark tillväxt, lönsamhet och brutalt cashflow. Det måste man ju gilla? Vi gillar, men marknaden verkar knappast imponerad sett till värderingen. Ytterligare ett iGaming-case med EV/EBIT-bordell…Sedan reser vi vidare till Unlimited Travel Group (01:34:19). Rapporten straffades, men det finns ändå en hel del ljusglimtar framåt. Förvärv och organisk tillväxt lockar. Transparensen i redovisningen under kvartalet är exemplarisk! Sist ut blir en intervju med Actics vd Niklas Johansson, som går igenom bolaget. Bolaget har genomgått en turnaround och aktien har minst sagt utvecklats positivt i år (01:58:19). Vi avslutar sedan med en Veckans Volley i sedvanlig ordning. Vi tipsar också om den nya tjänsten Quanor. En mycket spännande tjänst för börsnördar, som vi hoppas kommer att utvecklas till ett fantastiskt verktyg. Kika in https://www.quanor.com idag!Vi har med oss fina PinPoint idag som vanligt i rapportperioden. Din vän i rapportperioden så bara att gå in på https://pinpointestimates.com. Vi har också med oss SAVR som sponsor som du hittar hos https://savr.com. Handla aktier, fonder och ETF:er med automatiskt courtage!Kolla in vår SAVR-portfölj på Twitter/X och Bluesky: @GottTjotAktierMaila in till: gotttjotomaktier@gmail.comFölj oss på Twitter/X och Bluesky: @GottTjotAktier, @MarkusGedda & @aktiehesten-(00:08:57) - Nyheter(00:11:53) - Angler Gaming(00:23:53) - Envar(00:30:54) - Infracom(00:36:08) - Generic(01:02:44) - Hacksaw(01:34:19) - Unlimited Travel Group(01:58:19) - Intervju med Actics vd Niklas Johansson(02:39:33) - Veckans volleySupport this show http://supporter.acast.com/nantingomaktier. Hosted on Acast. See acast.com/privacy for more information.

Ny vecka och nya möjligheter. Det är full fart, vilket vi gillar. Vi har med oss alla våra fina sponsorer idag:Sveriges bästa handelsplattform: SAVRPinPoint - Din bästa vän i rapporttiderQuanor - Finansiell AI som alltid är till hjälp. Vi får välja bland casen och kör idag våra två främsta bidragsgivare till SAVR-portföljen: Cheffelo (00:45:47) och Premium Snacks (01:10:30). Först blir det löst snack som vanligt. Det är ändå vår paradgren med löst snack. Sedan rätt in i vassen med Cheffelo (00:45:47). Walker och Company gör oss inte besvikna. Det mest var redan känt men marknaden skickade ner aktien rejält. Men aktien studsade sedan upp igen. Stark leverans enligt oss och det går fortfarande lätt att räkna hem caset enligt oss. Operativt momentum och tung leverans!Sen blir det Premium Snacks (01:10:30). Många oroade sig efter Strinnings sälj, men en urstark rapport återigen. Mycket har hänt i år och det finns många spännande tillväxtoptioner framåt. Vi tror att även här så är det lätt att räkna hem caset om du blickar ut mot 2026!Vi avslutar sedan med en Veckans Volley i sedvanlig ordning. Vi tipsar också om den nya tjänsten Quanor. En mycket spännande tjänst för börsnördar, som vi hoppas kommer att utvecklas till ett fantastiskt verktyg. Kika in https://www.quanor.com idag!Vi har med oss fina PinPoint idag som vanligt i rapportperioden. Din vän i rapportperioden så bara att gå in på https://pinpointestimates.com. Vi har också med oss SAVR som sponsor som du hittar hos https://savr.com. Handla aktier, fonder och ETF:er med automatiskt courtage!Kolla in vår SAVR-portfölj på Twitter/X och Bluesky: @GottTjotAktierMaila in till: gotttjotomaktier@gmail.comFölj oss på Twitter/X och Bluesky: @GottTjotAktier, @MarkusGedda & @aktiehesten-(00:12:37) - Nyheter(00:45:47) - Cheffelo(01:10:30) - Premium Snacks(01:45:42) - Veckans VolleySupport this show http://supporter.acast.com/nantingomaktier. Hosted on Acast. See acast.com/privacy for more information.

GENERALI I LAP 76 POKLANJAJU BESPLATAN VAUČER ZA PREGLED PROSATE

Vi brötar på i sedvanligt manér utan vila. För den som missat det är det fortsatt rapportsäsong och fullt ös. Vi får sålla bland casen och kör idag Hellofresh (00:27:27), Lammhult (00:55:09) och Storytel (01:15:04). Vi har med oss fina PinPoint idag som vanligt i rapportperioden. Din vän i rapportperioden så bara att gå in på https://pinpointestimates.com. Vi har också med oss SAVR som sponsor som du hittar hos https://savr.com. Handla aktier, fonder och ETF:er med automatiskt courtage!Först blir det löst snack som vanligt. Ingen vet vad vi pratar om men det blir fotboll, Evolution, våra rapportswings och lite annat. Sedan rätt in i verkligheten med Hellofresh (00:27:27). En ganska trött Q3-rapport, men det ser ju ändå spännande ut inför 2026. Känns som vi endast kommer få se seklets största värdefälla eller moderns uppstuds här inom 12 månader. Inget mellanting. Sen blir det Lammhult (00:55:09). Lammen tystnade på rapportdag med -20%. Orimlig reaktion. Rimligheten återfanns och styrelseordförande och vd köper aktier. Lammhult studsade tillbaka och underliggande ses effekterna av förändringsarbetet. 2026 och 2027 borde se bra ut, annars kommer Lammhult röstas fram som seklets underpresterare. Vi tror dock på Per och Susanna med team.Snabbt över till Storytel (01:15:04). En banger till rapport där allt pekar åt rätt håll. Är Storytel för billigt? Kommer Spotify svälja dem på ett eller annat sätt? Frågorna är många men bolaget levererar ett fantastiskt Q3 Vi avslutar sedan med en Veckans Volley i sedvanlig ordning. Vi tipsar också om den nya tjänsten Quanor. En mycket spännande tjänst för börsnördar, som vi hoppas kommer att utvecklas till ett fantastiskt verktyg. Kika in https://www.quanor.com idag!Kolla in vår SAVR-portfölj på Twitter/X och Bluesky: @GottTjotAktierMaila in till: gotttjotomaktier@gmail.comFölj oss på Twitter/X och Bluesky: @GottTjotAktier, @MarkusGedda & @aktiehesten-(00:03:30) - SAVR-portföljen(00:12:21) - Nyheter(00:27:27) - Hellofresh(00:55:09) - Lammhult(01:15:04) - Storytel(01:44:27) - Veckans VolleySupport this show http://supporter.acast.com/nantingomaktier. Hosted on Acast. See acast.com/privacy for more information.

Four pillars of cardiology today, stable coronary artery disease, severe aortic stenosis, the evaluation of chest pain, and best therapies for atrial fibrillation are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Stable CAD Complete vs culprit-only revascularization at time of STEMI iMODERN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2512918 PRAMI Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1305520 COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775 FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149 PCI Revascularization Strategies After MI https://www.jacc.org/doi/10.1016/j.jacc.2024.04.051 CULPRIT SHOCK Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1710261 How a Meta-Analysis Can Mislead https://www.sensible-med.com/p/how-a-meta-analysis-can-misleadthe II SEVERE Aortic Senosis 7-Year PARTNER 3 Results – TAVI vs SAVR 7-year results PARTNER 3 https://www.nejm.org/doi/full/10.1056/NEJMoa2509766 PARTNER 3 at 1 year https://www.nejm.org/doi/10.1056/NEJMoa1814052 PARTNER 3 at 5 years https://www.nejm.org/doi/10.1056/NEJMoa2307447 III Functional vs Anatomic Assessment in Suspected CAD 10-year follow-up of PROMISE trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2838118 PROMISE Trial https://www.nejm.org/doi/10.1056/NEJMoa1415516 CCTA vs Functional Stress Test – Meta-Analysis https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2655243 IV ARREST AF ARREST AF trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2840225 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Det är rapportsäsong och två av iGaming-jättarna har inkommit. Fina Betsson och Evolution. Nelly har också glidit in och det var en riktig banger. Men först ut blir det löst snack. Allt mellan himmel och gjord. Sedvanligt sketsnack om allt från OnlyFans till C-RAD. Vi har med oss fina PinPoint idag som vanligt i rapportperioden. Din vän i rapportperioden så bara att gå in på https://pinpointestimates.com. Sedan blir det Betsson (00:28:04). Lindwall levererar stabilt, men inget som stack ut jättemycket finansiellt. Återköp på gång dock, och det verkade marknaden gilla. Hur man än vrider och vänder på detta kalaset så är det EV/EBIT bordell. Extremt stabilt och fina kassaflöden. Marknaden verkar endast hata Betssons kassaflöden eller tro att de ska minska rejält. Sedan blir det Nelly (00:53:39). Otrolig banger till rapport, men kursuppgången nästan utsuddad för att en större ägare verkar sälja. Vi tittar till och imponeras av Palm-effekten. Sedan dags för Evolution (01:14:40). Först avslöjandet om Playtech och sedan en rapport marknaden inte gillade. Det är tufft i Asien och fortsatt kämpigt generellt. Vi försöker ta oss igenom det som hänt. Det är inte lika billigt som Betsson, men nu är Evolution inte dyrt. Vi avslutar sedan med en Veckans Volley i sedvanlig ordning. Vi tipsar också om den nya tjänsten Quanor. En mycket spännande tjänst för börsnördar, som vi hoppas kommer att utvecklas till ett fantastiskt verktyg. Kika in https://www.quanor.com idag!Kolla in vår SAVR-portfölj på Twitter/X och Bluesky: @GottTjotAktierMaila in till: gotttjotomaktier@gmail.comFölj oss på Twitter/X och Bluesky: @GottTjotAktier, @MarkusGedda & @aktiehesten-(00:05:18) - Nyheter(00:28:04) - Betsson(00:53:39) - Nelly(01:14:40) - Evolution(01:46:22) - Veckans VolleySupport this show http://supporter.acast.com/nantingomaktier. Hosted on Acast. See acast.com/privacy for more information.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Fraser Sutherland, a consultant cardiac surgeon at Ross Hall Hospital and the Golden Jubilee National Hospital, Scotland, about the world's first transcervical robotic aortic valve replacement (AVR) procedures. Chapters 00:00 Intro  02:30 JANS 1, CABG After 60 Years  13:53 JANS 2, Endovascular Arch Repair  16:45 JANS 3, Impact of Age on ARR  18:47 JANS 4, Anterior Mediastinal Teratomas  20:28 Career Center  21:02 Video 1, RUL Without Dissecting SPV  22:58 Video 2, Replacement w Double Patch Repair  23:53 Video 3, TAVR & SAVR Removal w LVOR  24:47 Dr. Sutherland Interview  45:26 Closing  They discuss the history and evolution of these cases, along with the preclinical work that led to this innovative technique. Dr. Sutherland addresses initial challenges such as the uniportal incision, the transcervical retractor system, and enhancing dexterity by incorporating a robotic system. They also detail the first clinical case, including postoperative outcomes and the importance of maintaining safety for the patient. Additionally, they explore the benefits for patients undergoing this procedure and its future potential. Furthermore, Dr. Sutherland provides insights into the procedural steps and key aspects of the procedure.   Joel also highlights recent JANS articles on coronary artery bypass grafting 60 years after its debut, endograft design options and worldwide results for endovascular arch repair, the impact of age on aortic root replacement, and a multicenter retrospective study on if subxiphoid thoracoscopic surgery is safe and feasible for the treatment of anterior mediastinal teratomas.  In addition, Joel explores a multiportal approach for robotic right upper lobectomy without dissecting the superior pulmonary vein, aortic and mitral replacement with double patch repair, and TAVR and SAVR removal with left ventricular outflow reconstruction.  JANS Items Mentioned  1.) Coronary Artery Bypass Grafting: 60 Years After Its Debut  2.) Endovascular Arch Repair: Endograft Design Options and Worldwide Results  3.) The Impact of Age on Aortic Root Replacement  4.) Subxiphoid Thoracoscopic Surgery Is Safe and Feasible for the Treatment of Anterior Mediastinal Teratomas: A Multicentre Retrospective Study  CTSNet Content Mentioned  1.) Robotic Right Upper Lobectomy Without Dissecting the Superior Pulmonary Vein: A Multiportal Approach   2.) Aortic and Mitral Replacement With Double Patch Repair   3.) TAVR and SAVR Removal With Left Ventricular Outflow Reconstruction  Other Items Mentioned  1.) World's First Transcervical Robotic AVR Procedures Successfully Performed in 4 Cleveland Clinic Patients  2.) Resident Video Competition  3.) Perfecting TAVR Removal | Skills Sharpening With Vince Gaudiani  4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

IPD Meta-Analysis of Contemporary Trials Comparing TAVI versus SAVR

Can't get enough Linux? How about multiple kernels running simultaneously, side by side, not in a VM, all on the same hardware; this week it's finally looking real.Sponsored By:Managed Nebula: Meet Managed Nebula from Defined Networking. A decentralized VPN built on the open-source Nebula platform that we love. 1Password Extended Access Management: 1Password Extended Access Management is a device trust solution for companies with Okta, and they ensure that if a device isn't trusted and secure, it can't log into your cloud apps. Unraid: A powerful, easy operating system for servers and storage. Maximize your hardware with unmatched flexibility. Support LINUX UnpluggedLinks:

Dagens ämnen: 0:00 Intro 3:15 Intelligo och Integrum 16:55 Klarna 18:49 Oracle, Tesla och Nvidia 26:21 Oklo 28:13 Lundin Gold 29:43 Fedbesked 32:48 Veckans Fill or Kill 34:07 Intervju med Savr och Virtune!   www.instagram.com/fillorkillpodden   Tack RoboMarkets! http://gorobo.pro/2aue      @RoboMarketsSE  

In this episode, our hosts are joined by Sabine Bleiziffer and Augusto D'Onofrio to discuss SAVR after TAVR - exploring key decision-making factors, including valve selection, explantation techniques, and patient-specific risk profiles. The guests share experiences with challenging cases, technical tips, and thoughts on how procedural volume, planning, and shared decision-making can impact outcomes. We also consider the future of lifetime valve management and what young surgeons need to know as this field continues to evolve.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with CTSNet JANS Editor Dr. Mateo Marin-Cuartas, a cardiac surgeon in the University Department of Cardiac Surgery at the Leipzig Heart Center, Germany, about surgical aortic valve replacement (SAVR) vs transcatheter aortic valve replacement (TAVR). Chapters 00:00 Intro 00:57 Dr. Marin-Cuartas Feature 02:28 SHURUI Robot Feasability 05:09 Touching as Diagnostic Test 09:06 Removal of Rib Stab Hardware 13:00 Resectable EGFR-Positive NSCLC 16:12 On-Pump Beating Heart MVR 17:56 Post-Infarction Myocardial Rupture 19:52 Head-First Graft Technique 22:18 SAVR vs TAVR, Dr. Marin-Cuartas 46:44 Upcoming Events 47:52 Closing They discuss SAVR and TAVR guidelines, the suitability of SAVR vs TAVR for patients aged 65-75, and mechanical heart valves. They also explore surgery after TAVR, TAVR after TAVR, and the future of addressing aortic valve stenosis.   Joel also highlights recent JANS articles on the safety and feasibility of novel single-port robotic-assisted lobectomy/segmentectomy for lung cancer, touching (proximity) as a companion diagnostic test, long-term outcomes after removal of rib stabilization hardware in patients with blunt chest trauma, and advancing the needle on the management of resectable EGFR-positive NSCLC.    In addition, Joel explores an on-pump beating heart mitral valve repair through right anterior minithoracotomy, post-infarction myocardial rupture treated with surgical repair and graded mechanical support, and a head-first graft technique in aortic arch replacement. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) Safety and Feasibility of Novel Single-Port Robotic-Assisted Lobectomy/Segmentectomy for Lung Cancer  2.) Touching (Proximity) as a Companion Diagnostic Test   3.)  Long-Term Outcomes After Removal of Rib Stabilization Hardware in Patients With Blunt Chest Trauma  4.) Advancing the Needle on the Management of Resectable EGFR-Positive NSCLC: Is Neoadjuvant Osimertinib the Answer?  CTSNET Content Mentioned  1.) On-Pump Beating Heart Mitral Valve Repair Through Right Anterior Mini Thoracotomy  2.) Drain, Patch, Unload: Post-Infarction Myocardial Rupture Treated With Surgical Repair and Graded Mechanical Support  3.) Head-First Graft Technique in Aortic Arch Replacement  Other Items Mentioned  1.) Career Center   2.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

In this special one-year anniversary episode of The Atrium, host Dr. Alice Copperwheat speaks with Dr. Michael Mack, medical director of cardiothoracic surgery at Baylor Scott and White Health System and chairman of the Baylor Plano Research Center in Texas, about the future of valve surgery. Chapters 00:00 Introductions 01:18 Dr. Mack Background 03:41 Becoming a CT Surgeon 07:53 Path to Academic Surgery 10:19 Unconventional Thinking 11:30 TAVR vs SAVR 21:54 Surgical Replacement Future 25:59 Minimally Invasive Preference 27:27 Long-Term Data Impact 30:58 Aortic Valve Research Status 35:35 Mitral Clip vs Repair, Tricuspid 41:40 Mitral Robotic 44:38 Artificial Intelligence 48:43 Specializing Your Career 52:53 Three Career Tips They discuss transcatheter aortic valve replacement (TAVR), surgical aortic valve replacement (SAVR), MitraClips, the mitral valve, and the tricuspid valve. They also explore future research, the role of artificial intelligence (AI) and Dr. Mack provides advice for trainees.   The Atrium is a monthly podcast presenting clinical and career-focused topics for residents and early career professionals across all cardiothoracic surgery subspecialties. Watch for next month's episode on radial artery harvesting with Dr. Faisal Bakaeen of the Cleveland Clinic. Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning celebrates two years of the podcast and speaks with Dr. Joseph F. Sabik III, president of the Society of Thoracic Surgeons (STS) and chair of the Department of Surgery at University Hospitals Cleveland Medical Center, about the future of cardiothoracic surgery. Chapters 00:00 Intro 01:16 Dr. Sabik Guest 04:13 AATS 2025 20:26 Extended Sleeve Lobectomy Study 23:55 SQUAT Trial Results 26:28 TAVR vs SAVR in Women 27:49 Transition from Training to Practice 31:39 Totally Endoscopic Triple Valve 33:33 Redo AVR via Ministernotomy 35:18 ECMO Podcast Episode 37:19 Dr. Sabik, Future of CT Surgery 56:06 Upcoming Events 57:47 Closing They discuss the future of revascularization, advancements in valve procedures, arterial grafting, robotics training, and the importance of work-life balance. They also highlight the training of the next generation of surgeons, simulation-based education, and Dr. Sabik shares insights into the 62nd STS Annual Meeting. Additionally, Joel recaps the American Association for Thoracic Surgery (AATS) Annual Meeting emphasizing notable presentations and key insights from the event.   Joel also highlights recent JANS articles on extended sleeve lobectomy after neoadjuvant immunochemotherapy for centrally located non-small cell lung cancer, neoadjuvant concurrent chemo-immuno-radiation therapy followed by surgery and adjuvant immunotherapy for resectable Stage III N2 NSCLC, transcatheter vs. surgical aortic valve replacement in women, and a guide for transition from cardiothoracic surgery training to practice.   In addition, Joel explores totally endoscopic triple valve surgery, redo aortic valve replacement through a ministernotomy, and a new podcast episode from Dr. Alice Copperwheat, “The Atrium: ECMO,” with expert guest Dr. Jose Fernandes. Before closing, he highlights upcoming events in CT surgery.   JANS Items Mentioned  1.) Extended Sleeve Lobectomy After Neoadjuvant Immunochemotherapy for Centrally Located Non-Small Cell Lung Cancer  2.)  Neoadjuvant Concurrent Chemo-Immuno-Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L)   3.) Transcatheter vs. Surgical Aortic Valve Replacement in Women: The RHEIA Trial  4.) A Guide for Transition from Cardiothoracic Surgery Training to Practice  CTSNET Content Mentioned  1.) Totally Endoscopic Triple Valve Surgery: AVR, MVr, TVr  2.) Redo Aortic Valve Replacement Through a Ministernotomy    3.) The Atrium: ECMO  Other Items Mentioned  1.) Webinar Series: Women in Cardiothoracic Surgery—Advancement Through Collaboration   2.) Endoscopic Cardiac Surgery Series: The Swiss Army Knife Approach  3.) Aortic Valve Replacement Series   4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Dagens ämnen: 0:00 Intro 4:33 Evolution 14:29 Invisio 16:59 Haypp 18:04 Mag-7 21:18 Netflix 27:42 Fastigheter 30:56 Buffett 35:28 Tyskland 43:37 Intervju med IG! 1:03:10 Veckans Fill or Kill www.instagram.com/fillorkillpodden  Tack IG! https://upl.inc/ig_fillorkill  Tack @savr! http://www.savr.com Med kampanjkoden ”fillorkill200” får du 200 kr att investera för när du startar konto hos SAVR. Kampanjen gäller dig som inte är eller varit kund hos SAVR tidigare och koden är giltig t.o.m. 13/5 2025.

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Mario Castillo-Sang, the Surgical Director of Mitral Valve and Heart Failure Therapies at St. Elizabeth Healthcare, Edgewood, Kentucky, USA, about totally endoscopic cardiac surgery. Chapters 00:00 Intro 01:17 Minimal Access Bedside Cardiac 04:37 Lung Cancer, Histological Subtype 09:29 TAVR vs SAVR, AS & CAD 12:22 Biopros TVR Outcomes 15:48 Mitral Annular Disjunction, MVR 18:47 Ozaki Technique, AV Reconst 20:46 Redo LVOT Reconst for Endocarditis 22:33 Totally Endoscopic ASD Closure TVR 24:08 Dr. Castillo-Sang, MI Bedside Endoscopy 40:51 Closing They explore key highlights from Dr. Castillo-Sang's CTSNet series Endoscopic Cardiac Surgery Series: The Swiss Army Knife Approach, his journey in performing endoscopic surgeries, and how he learned the techniques. Dr. Castillo-Sang shares the advantages of endoscopic surgery, as well as tips and recommendations for those wanting to learn this approach. He emphasizes the importance of the instruments he has worked with, detailing how these have improved over time. Additionally, they explore Dr. Castillo-Sang's involvement with the Endoscopic Cardiac Surgeons Club, discussing how he got involved and providing details about the club's upcoming annual meeting.   Joel also highlights recent JANS articles on the estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time, transcatheter vs surgical aortic valve replacement in Medicare beneficiaries with aortic stenosis and coronary artery disease, long-term outcomes after bioprosthetic tricuspid valve replacement, and outcomes of patients with mitral annular disjunction undergoing mitral valve repair.  In addition, Joel explores aortic valve reconstruction using the Ozaki technique, redo LVOT reconstruction for endocarditis, and totally endoscopic ASD closure with tricuspid valve repair. Before closing, he highlights upcoming events in CT surgery.   JANS Items Mentioned  1.) Estimated Worldwide Variation and Trends in Incidence of Lung Cancer by Histological Subtype in 2022 and Over Time: A Population-Based Study  2.) Transcatheter vs Surgical Aortic Valve Replacement in Medicare Beneficiaries With Aortic Stenosis and Coronary Artery Disease  3.) Long-Term Outcomes After Bioprosthetic Tricuspid Valve Replacement: A Multicenter Study  4.) Outcomes of Patients With Mitral Annular Disjunction Undergoing Mitral Valve Repair  CTSNET Content Mentioned  1.) Aortic Valve Reconstruction—The Ozaki Technique  2.) Redo LVOT Reconstruction for Endocarditis  3.) Totally Endoscopic ASD Closure With Tricuspid Valve Repair  Other Items Mentioned  1.) Endoscopic Cardiac Surgery Series: The Swiss Army Knife Approach  2.) Endoscopic Cardiac Surgeons Club  3.) Mini Heart Valves   4.) Aortic Valve Replacement Series     5.) Career Center 6.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

In this podcast, Dr. Valentin Fuster reviews a pivotal study comparing the five-year outcomes of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in low-risk patients with severe aortic stenosis. The study found that both treatments yielded similar mortality and stroke rates, reinforcing TAVR's non-inferiority to surgery, though long-term outcomes in younger patients and the impact of pacemaker implantation remain areas of concern.

-Halo Ferrari?-Tsunoda makar stigao do Q2-Lawson i dalje u paduOMV, ZVANIČNI PARTNER LAP 76 ⛽️Preuzmite OMV MyStation mobilnu aplikaciju, podržite Lap 76 - https://www.omv.co.rs/sr-rs/mystationPretvorite poene u trenutke radosti - svaka kupovina na OMV stanicama vam donosi poene, koje možete pretvoriti u trenutke radosti u prodavnici OMV-a.Pri kupovini goriva, preporučujemo MaxxMotion, za koji ostvarujete i popust!

+Francesco Bagnaia prvi put pobedio u Ostinu u MotoGP klasi+Moto 2: Dixon prvi put dve pobese zaredom u šampionatu sveta!+Moto 3: Rueda, očekivano i dominantno.OMV, ZVANIČNI PARTNER LAP 76 ⛽️Preuzmite OMV MyStation mobilnu aplikaciju i podržite Lap 76 - https://www.omv.co.rs/sr-rs/mystationIstovremeno pretvorite poene u trenutke radosti - svaka kupovina na OMV stanicama vam donosi poene, koje možete da pretvorite u nove trenutke radosti u prodavnici OMV-a.A uz svaku kupovinu goriva, preporučujemo MaxxMotion, ostvarujete i popust!

Listener feedback on asymptomatic aortic stenosis (AS), transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR), coronary artery calcium (CAC), and revascularization for patients with ischemic LV dysfunction are discussed by John Mandrola, MD, in today's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Aortic Valve Intervention for Asymptomatic AS Asymptomatic Aortic Stenosis: “Time to Act” or Not So Fast? https://www.medscape.com/viewarticle/asymptomatic-aortic-stenosis-time-act-or-not-so-fast-2025a10005o9 EARLY TAVR: A Positive Trial That Fails to Inform Clinical Decisions https://www.medscape.com/viewarticle/early-tavr-positive-trial-fails-inform-clinical-decisions-2024a1000kec Reddy et al: https://doi.org/10.1016/j.jacc.2024.12.031 Wallach editorial https://doi.org/10.1016/j.jacc.2025.01.020 Guerrero https://www.tctmd.com/slide/tavr-young-patients-current-treatment-patterns-us II CAC - Coronary Artery Calcium Coronary Artery Calcium Testing—Too Early, Too Late, Too Often https://jamanetwork.com/journals/jamacardiology/fullarticle/2830950 CAUGHT-CAD https://jamanetwork.com/journals/jama/fullarticle/2831115 III CABG, PCI or Meds for Ischemic LV Dysfunction STICH https://www.nejm.org/doi/full/10.1056/NEJMoa1100356 STICHES https://www.nejm.org/doi/full/10.1056/NEJMoa1602001 REVIVED BCIS https://www.nejm.org/doi/full/10.1056/NEJMoa2206606 EHJ paper https://doi.org/10.1093/eurheartj/ehaf080 IV Preview https://www.medscape.com/viewarticle/shed-lead-and-injuries-should-cath-labs-go-lead-free-2024a1000hnb You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

+Savršen vikend za Marca Marqueza - pol-pozicija, pobeda u sprintu, pobeda u GP trci.+Alex Marquez drugi u obe trke za porodično slavlje.+Dominacija i u Moto 2 Gonzaleza i u Moto 3 Ruede.OMV, ZVANIČNI PARTNER LAP 76 ⛽️Preuzmite OMV MyStation mobilnu aplikaciju i podržite Lap 76 - https://www.omv.co.rs/sr-rs/mystationIstovremeno pretvorite poene u trenutke radosti - svaka kupovina na OMV stanicama vam donosi poene, koje možete da pretvorite u nove trenutke radosti u prodavnici OMV-a.A uz svaku kupovinu goriva, preporučujemo MaxxMotion, ostvarujete i popust!

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Dr Anvesha Singh from the University of Leicester. They discuss her paper on trends in SAVR and TAVI for aortic stenosis over the last two decades and whether outcomes have changed across various sociodemographic groups. If you enjoy the show, please leave us a podcast review wherever you get your podcast - it's very helpful to us! Link to published paper: https://heart.bmj.com/content/early/2024/11/27/heartjnl-2024-324918?rss=1

The TCW Trial compared TAVI + FFR-guided PCI versus SAVR + CABG in patients with severe aortic stenosis and complex coronary artery disease. This multicenter, randomized controlled trial included 172 patients aged ≥70 years. At 1 year, the primary composite endpoint (death, MI, stroke, revascularization, valve reintervention, or major bleeding) was significantly lower in the TAVI + PCI group (4%) compared to SAVR + CABG (23%), meeting both noninferiority and superiority criteria. The study suggests TAVI + PCI as a safer, less invasive alternative with reduced mortality and bleeding risks in selected patients.

+Savršena najava 2025. godine. Ko zna ko će biti prvak.+Lewis i Charles sa začelja na četvrto i treće mesto.+Gasly obezbedio šesto mesto za Alpine!https://fantasy.formula1.com/en/leagues/join/P5SEDGFHU02KOD ZA LIGU: P5SEDGFHU02Ukoliko želite da podržite ekipu Infinity Lighthouse i sve što radimo, najbrže je kroz Patreon i YouTube članstvo.Patreon: https://www.patreon.com/infinitylighthouse YT: https://www.youtube.com/channel/UCQ2D37u3DU1XGxxriq5779Q/joinDomaćini: Pavle Živković i Srđan Erceg#lap76#infinitylighthouse#f1 00:00:00 Početak------------------------------HUMANITARNI KUTAKPomozimo Martinu!Slanjem SMS poruke: Upišimo 1503 i pošaljimo SMS na 3030Slanjem SMS poruke iz Švajcarske: Upišimo human1503 i pošaljimo SMS na 455Uplatom na dinarski račun: 160-6000001670866-23Uplatom na devizni račun: 160-6000001671337-65IBAN: RS35160600000167133765SWIFT/BIC: DBDBRSBGUplatom platnim karticama putem linka: E-doniraj (https://www.budihuman.rs/edonate/sr?user_id=1503)Uplatom sa vašeg PayPal naloga putem linka: PayPal (https://www.budihuman.rs/paypal/sr/donate?user_id=1503)-----------------NAŠA PRODAVNICA - ️https://shop.infinitylighthouse.comSvi koji žele da obogate svoju biblioteku prelepim delima o Formuli 1 i MotoGP-u ili se obuku u naše, zajedničke, boje, tu je naša zvanična prodavnica knjiga, majica i kačketa.NAŠE DRUŠTVENE MREŽE Instagram - https://instagram.com/infinitylighthouse Facebook - https://facebook.com/theinfinitylighthouseTwitter - https://twitter.com/infinitylighthsSPORTSKE VESTI - https://sportsmagazin.rsMusic credit: Envato Elements Item/Cinematic Heroic by StudioKolomnaAutor: Srđan ErcegDatum: 8. decembar 2024.Lokacija: Studio na kraju UniverzumaProdukcija: Infinity Lighthouse https://www.youtube.com/infinitylighthouseWebsite: https://infinitylighthouse.com/Zabranjeno je svako kopiranje i neovlašćeno preuzimanje video i/ili audio snimaka i postavljanje na druge kanale! Nije dozvoljeno koristiti materijal sa ovog kanala, bilo u celosti ili iz segmenata, bez licenciranja / plaćanja kako za komercijalnu, tako i za nekomercijalnu upotrebu.Svaka upotreba bez licenciranja za komercijalnu ili nekomercijalnu / privatnu upotrebu biće procesuirana. Za sve informacije o pravima, za upite o licenciranju i dobijanju dozvole za korišćenje možete nas kontaktirati putem naše zvanične email adrese.Copying, re-uploading, and illegally distributing this copyrighted work is strictly prohibited! Label and copyright: Infinity Lighthouse. ★ Support this podcast on Patreon ★

This episode delves into the pressing need to reevaluate the management strategies for Aortic Valve Disease (AVD) worldwide. With a focus on South Asian and Sub-Saharan African nations, the discussion highlights how low-income countries predominantly rely on surgical aortic valve replacement (SAVR) using mechanical valves. The episode explores the unique challenges faced in these regions, where patients are generally younger compared to those in high-income countries, and the disease often stems from rheumatic origins. The conversation aims to shed light on the disparities in treatment approaches and the necessity for tailored solutions that address the distinct characteristics of AVD in diverse global contexts.

Domaćini: Mihailo Stefanović, Vanja Milićević, Ivan Nedeljković i Srđan Erceg+Igrajte sa nama "LIGU 99 JARDI" u prognozama pobednika: www.99jardi.com00:00:00 Uvod00:07:50 PEPSI priča nedelje00:40:30 MIN - GB00:45:50 NO - ATL00:55:54 PIT - IND01:01:50 BUF - BAL01:07:40 DET -SEA01:12:24 Rezultati odigranog kola 01:17:00 Tabele NFC/AFC01:20:26 Heroji01:22:56 Džokeri01:26:23 Tragičari01:34:26 Novajlije nedelje01:37:48 Novajlije meseca01:42:04 Naše i vaše prognoze + tabele01:48:00 TNF01:58:57 Izdvojene utakmice za pedstojeće kolo02:27:06 Najava kompletnog kola02:36:15 Naše prognoze za predstojeće kolo 02:40:30 Pitanja i odgovoriSPORTSKE VESTIhttps://sportsmagazin.rs#99jardi #nfl#infinitylighthouse ------------------------------HUMANITARNI KUTAKPomozimo Anici!Slanjem SMS poruke: Upišimo 1454 i pošaljimo SMS na 3030Slanjem SMS poruke iz Švajcarske: Upišimo human1454 i pošaljimo SMS na 455Uplatom na dinarski račun: 160-6000001614978-71Uplatom na devizni račun: 160-6000001616335-74IBAN: RS35160600000161633574SWIFT/BIC: DBDBRSBGUplatom platnim karticama putem linka: E-doniraj (https://www.budihuman.rs/edonate/sr?user_id=1454)Uplatom sa vašeg PayPal naloga putem linka: PayPal (https://www.budihuman.rs/paypal/sr/donate?user_id=1454)-----------------PODRŠKA ZA INFINITY LIGHTHOUSEUkoliko želite da podržite ekipu Infinity Lighthouse i sve što radimo, najbrže je kroz Patreon i YouTube članstvo.Patreon: https://www.patreon.com/infinitylighthouse YT: https://www.youtube.com/channel/UCQ2D37u3DU1XGxxriq5779Q/join-----------------NAŠA PRODAVNICASvi koji žele da obogate svoju biblioteku prelepim delima o Formuli 1 i MotoGP-u ili se obuku u naše, zajedničke, boje, tu je naša zvanična prodavnica knjiga, majica i kačketa.️https://shop.infinitylighthouse.com https://shop.infinitylighthouse.com/majice.htmlhttps://shop.infinitylighthouse.com/knjige.htmlhttps://shop.infinitylighthouse.com/kacketi.htmlNAŠE DRUŠTVENE MREŽE Instagram - https://instagram.com/infinitylighthouse Facebook - https://facebook.com/theinfinitylighthouseTwitter - https://twitter.com/infinitylighthsMusic credit: Cinematic Heroic by StudioKolomna (Envato Elements Item)Datum: 4. oktobar 2024.Lokacija: Studio na kraju UniverzumaProdukcija: Infinity Lighthouse https://www.youtube.com/infinitylighthouseWebsite: https://infinitylighthouse.com/ ★ Support this podcast on Patreon ★

+Ko stiže u fabrički Ducati?+Moto2: Joe Roberts novi šampion iz Amerike?+Moto3: Alonso. Tačka.OMV MyStation aplikacija je stigla, pretvorite poene u trenutke radosti – preuzmite novu aplikaciju:https://www.omv.co.rs/sr-rs/mystationDuracell - Igraj i osvoji put u Moncu: https://igrajiosvoji.com/Link za zvaničnu Fantasy Lap 76 MotoGP ligu za 2024: https://fantasy.motogp.com/leagues/join/4WEEP7HUKod za ligu: 4WEEP7HUPodrška Infinity Lighthouse ekipi!

An Impella update, another TAVI vs SAVR trial, two studies on angina and PCI, another null substudy from REVIVED-BCIS, and semaglutide are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Impella Update CHRIP BCIS 3 https://classic.clinicaltrials.gov/ct2/show/NCT05003817 Danger-Shock Podcast https://www.medscape.com/viewarticle/1000675 II. TAVI vs SAVR Notion 2 Trial EHJ https://doi.org/10.1093/eurheartj/ehae331 DEDICATE-DZHK6 III. Angina and PCI Orbita 2 Sub-analysis Orbita Star https://www.jacc.org/doi/10.1016/j.jacc.2024.04.001 IV. Complete Revascularization Main REVIVED trial https://www.nejm.org/doi/full/10.1056/NEJMoa2206606 JACC Substudy https://www.jacc.org/doi/10.1016/j.jacc.2024.04.043 V. Semaglutide Semaglutide CV Benefits Irrespective of Weight Loss: 4-Year SELECT Data https://www.medscape.com/viewarticle/semaglutide-cv-benefits-irrespective-weight-loss-4-year-2024a100095z Nature Med substudy https://www.nature.com/articles/s41591-024-02996-7 SELECT Main paper https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

The DEDICATE trial of TAVR vs SAVR, more on renal denervation, inclisiran, and marketing disguised as science are the topics John Mandrola, MD, discusses in today's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. TAVR vs SAVR TAVI Comparable With SAVR in Lower-Risk Aortic Stenosis https://www.medscape.com/viewarticle/tavi-comparable-savr-lower-risk-aortic-stenosis-2024a100074o?form=fpf DEDICATE https://www.nejm.org/doi/full/10.1056/NEJMoa2400685 Partner 3 https://www.nejm.org/doi/full/10.1056/NEJMoa1814052 Evolut Low Risk https://www.nejm.org/doi/full/10.1056/NEJMoa1816885 Barili meta-analysis https://doi.org/10.1093/ejcts/ezab516 II. Renal Denervation Alcohol-Mediated Renal Denervation Promising in Hypertension https://www.medscape.com/viewarticle/alcohol-mediated-renal-denervation-promising-hypertension-2024a10007eg TARGET 1 https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.069291 III. Inclisiran Earlier Inclisiran Gives Better Long-Term LDL Reductions https://www.medscape.com/viewarticle/earlier-inclisiran-gives-better-long-term-ldl-reductions-2024a10007d6 VICTORIAN INITIATE Trial https://www.jacc.org/doi/10.1016/j.jacc.2024.03.382 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington  Questions or feedback, please contact news@medscape.net

In 1994, biotech company Calgene brought the world's first genetically-modified food to supermarket shelves.The Flavr Savr tomato kept fresh for 30 days and could be shipped long distances without going off.Yet the world was wary of this new food, and it took 10 years and $100m of investment to get it to market.In 2017, the firm's then-CEO Roger Salquist told Claire Bowes about his mission to revolutionise the world's food.(Photo: Roger Salquist with a crop of Flavr Savrs. Credit: Richard Gilmore)

More on the Million Hearts RCT, ENRICH AF, TAVI vs SAVR, the Partner 3 and Evolut-low-risk trials, and myocardial viability are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Listener Feedback Million Hearts CMS 'Million Hearts' CVD Risk Reduction Model Works https://www.medscape.com/viewarticle/997551 -  RCT JAMA -    https://jamanetwork.com/journals/jama/fullarticle/2810696 AC in ICH - ENRICH AF Oral Anticoagulation in ICH Patients With AF: New Data https://www.medscape.com/viewarticle/997547 -  Lancet Neurology Meta-analysis https://doi.org/10.1016/S1474-4422(23)00315-0 -  ENRICH AF letter https://doi.org/10.1016/S0140-6736(23)02025-1 II.  TAVI vs SAVR Low-Risk TAVR Studies: Divergent Long-Term Results  https://www.medscape.com/viewarticle/997784 -  Partner 3 Main Results -  Partner 3 – Five Year -  Original EVOLUT -LR https://www.nejm.org/doi/10.1056/NEJMoa1816885 -  EVOLUT 3-year https://doi.org/10.1016/j.jacc.2023.02.017 -  EVOLUT -LR 4-year https://doi.org/10.1016/j.jacc.2023.09.813 III. Myocardial Viability Viability-Guided PCI Doubted in Stable Severe CAD: REVIVED-BCIS2 https://www.medscape.com/viewarticle/989101 -  Revived BCIS – Original paper  https://www.nejm.org/doi/10.1056/NEJMoa2206606 -  JAMA Cardiology Viability paper https://jamanetwork.com/journals/jamacardiology/fullarticle/2810727 -  STICH Viability Paper - https://www.nejm.org/doi/full/10.1056/NEJMoa1100358 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net